Quebec Network Réseau Québécoise de l’Amyotrophie Spinale Joins NMD4C as Community of Practice Sub-Group
We are thrilled to announce that the Réseau Québécoise de l’Amyotrophie Spinale (RQAS), a network uniting rehabilitation clinicians across Quebec to advance the care of people with Spinal Muscular Atrophy (SMA) since 2022, has officially become a sub-group Community of Practice of the Neuromuscular Disease Network of Canada (NMD4C).
This marks an exciting milestone for both the NMD4C and RQAS members, offering significant new opportunities and resources.
By welcoming the RQAS, the NMD4C gains:
- A well-established community of practice of 136+ members, including clinicians, researchers, and patient partners.
- Stronger French-Canadian representation, ensuring diverse perspectives in care, research, and policy.
- A proven model for clinician-driven collaboration, expanding best practices across neuromuscular diseases.
As a sub-group of the NMD4C, the RQAS will benefit from:
- Greater access to support for research, training, and initiatives to improve neuromuscular care.
- Enhanced organizational support, streamlining activities for greater efficiency.
- A broader national network, fostering collaboration, knowledge-sharing, and innovation.
Through incorporating RQAS into NMD4C, we will continue our efforts to unify, support, and advance neuromuscular care and research across Canada. We look forward to working together to drive innovation and improve outcomes for individuals with neuromuscular diseases. If you have any questions, contact our Community of Practice Manager.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.